Oral administration of hydrolytic enzymes (HE), such as bromelain, trypsin and rutosid, may have beneficial effects on the clinical course of neurological symptoms related to multiple sclerosis (MS). This is supported by a complete protection by HE from experimental allergic encephalomyelitis, an animal model related to MS. Three hundred and one patients with relapsing MS were enrolled in a double-blind, placebo-controlled trial. No treatment effect between the placebo and the HE groups was found either for clinical or MRI parameters.
Baumhackl U , Födermair S.Enzymtherapie bei Multipler Sklerose . Allgemeinmedizin1990; 19: 169-172 .
3.
Taragoni OS , Tary-Lehmann M , Lehmann PV.Prevention of murine EAE by oral hydrolytic enzyme treatment . J Autoimmun1999; 12: 191-198 .
4.
Desser L , Rehberger A , Kokron E.Cytokine synthesis in human peripheral blood mononuclear cells after oral administration of polyenzyme preparations . Oncology1993; 50: 403-407 .
Stauder G , Donnerstag B , Baumhackl U , Buschmans E.Use of oral enzymes in multiple sclerosis: phenotyping of peripheral blood lymphocytes from MS patients under longterm treatment with orally administered hydrolytic enzymes . Int J Immunotherapy1997; 13: 135-137
7.
Poser C , Paty D , Scheinberg L , McDonald W , Davis D , Ebers Get al.New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol1983; 13: 227-231 .
